DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

Phase 2

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: HKI-272
Procedure: Surgical Resection
Drug: Capecitabine
Drug: Ado-Trastuzumab Emtansine

First Posted Date: 2011-12-19

Last Posted Date: 2024-05-22

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 140

Registration Number: NCT01494662

Locations: 🇺🇸
University of North Carolina at Chapel Hill - Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
UPMC Passavant Cranberry, Cranberry Township, Pennsylvania, United States

and more 15 locations

Dasatinib in Advanced Squamous Cell Lung Cancer

Phase 2

Terminated

Conditions: Squamous Cell Lung Cancer

Interventions: Drug: Dasatinib

First Posted Date: 2011-12-14

Last Posted Date: 2014-07-15

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 5

Registration Number: NCT01491633

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma

Phase 2

Terminated

Conditions: Thrombocytopenia
Multiple Myeloma

Interventions: Drug: Eltrombopag

First Posted Date: 2011-12-02

Last Posted Date: 2017-03-15

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 1

Registration Number: NCT01484314

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro

Completed

Conditions: Multiple Myeloma

Interventions: Procedure: Blood draws

First Posted Date: 2011-11-16

Last Posted Date: 2018-01-11

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 11

Registration Number: NCT01472627

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia

Phase 2

Completed

Conditions: Waldenstrom's Macroglobulinemia

Interventions: Drug: Dexamethasone
Drug: Carfilzomib
Drug: Rituximab

First Posted Date: 2011-11-11

Last Posted Date: 2018-11-20

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 31

Registration Number: NCT01470196

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

The Young Women's Breast Cancer Study

Active, not recruiting

Conditions: Breast Cancer

First Posted Date: 2011-11-09

Last Posted Date: 2024-04-24

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 1302

Registration Number: NCT01468246

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
DF/BWCC at Milford Regional Medical Center, Milford, Massachusetts, United States
🇺🇸
Newton-Wellesley Hospital, Newton, Massachusetts, United States

and more 10 locations

Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Phase 2

Completed

Conditions: Pancreatic Neuroendocrine Tumor
Carcinoid Tumor

Interventions: Drug: Cabozantinib

First Posted Date: 2011-11-06

Last Posted Date: 2024-03-05

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 61

Registration Number: NCT01466036

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL

Phase 2

Terminated

Conditions: CLL
SLL

Interventions: Drug: Ofatumumab
Drug: High-Dose Methylprednisolone
Drug: Alemtuzumab

First Posted Date: 2011-11-04

Last Posted Date: 2023-08-29

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 30

Registration Number: NCT01465334

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Multiple Risk Behavior Intervention in Health Care Settings

Not Applicable

Completed

Conditions: Health Behavior
Risk Reduction Behavior

Interventions: Behavioral: HD2+
Behavioral: HD2

First Posted Date: 2011-08-12

Last Posted Date: 2018-12-19

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 2440

Registration Number: NCT01415492

Locations: 🇺🇸
Harvard Vanguard Medical Associates, Boston, Massachusetts, United States

SNP-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants (HSCT)

Completed

Conditions: Non-Hodgkin's Lymphoma
Hodgkin's Lymphoma
Multiple Myeloma

First Posted Date: 2011-07-26

Last Posted Date: 2013-07-16

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 181

Registration Number: NCT01402687

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy